Cargando…
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
BACKGROUND: The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a nonamplified MAF gene in the primary tumor and benefit from adjuvant ZA. Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study. METHODS: A retrospective...
Autores principales: | Paterson, Alexander H G, Lucas, Peter C, Anderson, Stewart J, Mamounas, Eleftherios P, Brufsky, Adam, Baez-Diaz, Luis, King, Karen M, Lad, Thomas, Robidoux, André, Finnigan, Melanie, Sampayo, Miguel, Tercero, Juan Carlos, Mairet, Joël Jean, Wolff, Antonio C, Fehrenbacher, Louis, Wolmark, Norman, Gomis, Roger R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346694/ https://www.ncbi.nlm.nih.gov/pubmed/34377934 http://dx.doi.org/10.1093/jncics/pkab054 |
Ejemplares similares
-
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019) -
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021) -
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020) -
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023) -
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985)